These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 31344332)

  • 41. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
    Taylor BA; Thompson PD
    Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2015; 16(10):1449-61. PubMed ID: 26037614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia.
    Robinson JG
    Prog Cardiovasc Dis; 2016; 59(2):165-171. PubMed ID: 27498088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing dyslipidaemia in patients with chronic kidney disease.
    Mehta A
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S90-S92. PubMed ID: 38278323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poststatin Lipid Therapeutics: A Review.
    Jia X; Lorenz P; Ballantyne CM
    Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
    Lee S; Cannon CP
    Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients.
    Kaysen GA
    Blood Purif; 2017; 43(1-3):196-199. PubMed ID: 28114129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
    Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Ezetimibe as a treatment for dyslipidaemia in CKD].
    Żebrowski P; Kaszyńska M
    Wiad Lek; 2019; 72(11 cz 2):2210-2213. PubMed ID: 31860838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
    Choi J; Khan AM; Jarmin M; Goldenberg N; Glueck CJ; Wang P
    Lipids Health Dis; 2017 Jul; 16(1):141. PubMed ID: 28738813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
    Serban MC; Banach M; Mikhailidis DP
    Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unmet Needs in LDL-C Lowering: When Statins Won't Do!
    Krähenbühl S; Pavik-Mezzour I; von Eckardstein A
    Drugs; 2016 Aug; 76(12):1175-90. PubMed ID: 27456066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.